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Automation  will likely  to play  a key  role  in the  development  of  scalable  manufacturing  processes  for
cell-based  therapies.  In this  study,  we  have  compared  the  effects  of manual  centrifugation  and  auto-
mated  non-centrifugation  cell  culture  process  steps,  performed  using  TAP biosystems’  CompacT  SelecT
automated  cell  culture  platform,  upon  hMSC  morphology,  number,  viability,  surface  marker  expression,
Short tandem  repeat  (STR)  proﬁle,  and  paracrine  function.  Furthermore,  the  comparability  between  ﬂow
cytometry  analyses  of  hMSCs,  performed  at multiple  sites,  was  investigated.  No  signiﬁcant  difference  in
hMSC  growth  and  characteristics  was  observed  between  cells  cultured  using  either  the  manual  centrifu-
gation  process  step  or the  automated  non-centrifugation  process  step,  in  which  residual  dissociation
agent  is  carried  over.  However,  some  variability  in  paracrine  activity  was  observed  between  hMSCs
cultured  using  alternative  process  steps.  It  is  also  apparent  that  differences  in analytical  methods  cancale-up
arge-scale cultivation
inﬂuence  the  inter-laboratory  reproducibility  of  hMSC  ﬂow  cytometry  analysis,  although  differences  in
culture may  also  contribute  to  the  variability  observed  in the  expression  of 2  of the  8 surface  markers
examined.  This  novel  investigation  into  the  effects  of  these  two key  process  steps  will  help  to improve
the  understanding  of the  inﬂuence  of  automated  cell  culture  upon  various  cell culture  parameters,  as
well  as upon  process  comparability.
© 2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license. Introduction
Mesenchymal stromal cells (MSCs) were ﬁrst described by
riedenstein et al. in the 1970s as an adherent, non-haematopoietic
ell type, present in the bone marrow, with the capacity to form
broblastic colonies in vitro, and were assigned the name ‘colony-
Abbreviations: BM-MNCs, bone marrow mononuclear cells; CLA, cell line
uthentication; DMEM HG GlutaMAXTM, Dulbecco’s modiﬁed eagle’s medium
igh glucose glutamaxTM; DMSO, dimethyl sulfoxide; FBS, fetal bovine serum;
MSC, human mesenchymal stromal cells; HY-PT, hypoxic pre-treatment; IDO,
ndoleamine 2,3 dioxygenase; IN-PT, inﬂammatory pre-treatment; NT, no treat-
ent; PGE-2, prostaglandin E2; STR, short tandem repeat; VEGF, vascular
ndothelial growth factor.
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forming unit-ﬁbroblasts’ [1]. After two decades of research, the
stromal location and trilineage differentiation potential of this cell
population were determined, and in the early 1990s, Caplan [2]
reported that these cells were capable of differentiating into all cells
of the mesodermal lineage, and thus labelled them ‘mesenchymal
stem cells’. Despite ongoing uncertainty regarding their ‘stemness’,
deﬁning surface marker proﬁle, in vivo identity, and tissue source,
the ISCT published a deﬁnition paper [3], outlining the basic crite-
ria for the identiﬁcation of MSCs. These included their adherence to
culture plastic, their positive expression of CD105, CD73 and CD90,
their lack of CD45, CD34, CD14 or CD11b, CD79  ˛ or CD19 and HLA-
DR expression, and their osteogenic, chondrogenic and adipogenic
differentiation potential in vitro. Although, this deﬁnition may  lack
accuracy and speciﬁcity to the MSC  cell type, it represents a step
closer to deﬁning the MSC  phenotype.
However, this current deﬁnition of human MSCs does not
account for the in vivo mode of action of this cell population. In
the mid-2000s, it was  determined that, in combination with the
traditional MSC  differentiation mode of action, various cytokines
and growth factors secreted by MSCs may  aid tissue repair and sup-
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ress immune reaction [4]. Although currently any deﬁnition of the
arious MSC  therapeutic effects is lacking, recent years have seen
he initial developments in the characterisation of MSC  mode of
ction with the ISCT proposing a series of assays capable of deter-
ining human MSC  immune regulatory properties [5]. However,
ubstantial progress is required before in vivo MSC  function is fully
nderstood and comprehensive potency assays for each of the MSC
utative mechanisms of action can be developed.
Considerable hurdles also exist in the manufacture of hMSC-
ased therapies, including the requirement for a large number
f cells for cell therapy, and the signiﬁcant workload, cost and
ariation that is associated with manual cell culture [6]. The devel-
pment of automated adherent cell culture platforms, for example
AP Biosystems’ CompacT SelecT (Royston, UK), has made automa-
ion a viable alternative to manual cell culture processes. However,
he examination of the way in which the differences between man-
al and automated cell culture processes may  affect relevant cell
ulture parameters is limited to a few studies and further investi-
ation is required [7–10].
Many of the process steps within the CompacT SelecT auto-
ated hMSC passage protocols developed in the present study are
ery similar to that of manual passage protocols. However, these
wo culture methods differ in one key process step. During man-
al cell culture, once the dissociation agent (e.g. Trypsin EDTA)
as been applied and the cells have been incubated, the enzyme
s neutralised, the suspension is centrifuged and the supernatant is
spirated in order to isolate a cell pellet. However, during the auto-
ated cell culture process, once the dissociation agent has been
pplied, it is immediately poured off so that only a residual amount
emains. The cells, and remaining enzyme, are then incubated and
edia is then applied in order to neutralise the dissociation agent.
The speciﬁc effect of this dissociation agent carryover and lack
f centrifugation in the automated cell culture process has yet to be
nvestigated. Therefore, in this study, we aim to compare the effects
f centrifugation and non-centrifugation process steps upon hMSC
umber, viability, surface marker expression, Short tandem repeat
STR) proﬁle, and paracrine function. In order to facilitate direct
omparison and explore process comparability, only the centrifu-
ation and dissociation process steps differed between the manual
nd automated culture methods in order to minimise any manual
ariation. This novel investigation into the effects of these two key
rocess steps will help to improve the understanding of the inﬂu-
nce of automated cell culture upon various cell culture parameters
nd may  enable further optimisation of this process in the future.
Furthermore, the present study will explore the comparability
etween independent ﬂow cytometry analyses of hMSC surface
arker expression. It is apparent that signiﬁcant inter-operator
ariation and differences in methods of analysis exist between
sers and laboratories, and that these may  contribute to the vari-
bility in the results of ﬂow cytometry analyses observed between
aboratories [11]. Therefore, this study compared the results of
MSC ﬂow cytometry analyses performed at two independent
aboratories, in order to examine the effect of inter-laboratory vari-
bility.
Additionally, as part of the ﬂow cytometry comparability inves-
igation, a hMSC culture protocol transfer between Loughborough
niversity (UK) and LGC (Teddington, UK) was performed. How-
ver, as no CompacT SelecT was available at LGC, the automated
entrifugation and non-centrifugation protocols utilised at Lough-
orough University were replicated manually. This determined
hether any observed differences in hMSC characteristics between
utomated centrifugation and non-centrifugation process steps
ere maintained in the manual versions of these process steps.
his therefore allowed for the comparability between manual and
utomated versions of the centrifugation and non-centrifugation
rocess steps to be investigated.eering Journal 108 (2016) 69–83
The present study will also examine the expression of various
cytokines and growth factors which have been associated with a
number of the more established MSC  modes of action, including
immune modulation, angiogenesis, and anti-apoptosis. In partic-
ular, the hMSC-mediated secretion of prostaglandin E-2 (PGE-2)
and vascular endothelial growth factor (VEGF) into the cell culture
medium, as well as the hMSC-mediated indoleamine 2,3 dioxyge-
nase (IDO) activity, after pre-treatment, was  measured prior to, and
after, culture using each of the alternative process steps.
Culture expanded hMSC IDO secretion, stimulated by pro-
inﬂammatory interferon gamma  (IFN-) [12], has been strongly
linked to the suppression of T, B and dendritic cells [13]. Natural
killer (NK) cell function has also been found to be inhibited by both
IDO and PGE-2 secretion by MSCs [14]. The suppression of T cell
response, through the upregulation of IDO, has been associated
with the depletion of tryptophan and the accumulation of toxic
metabolites [15]. More recently, IDO has been found to be a central
effector of MSC  T cell suppressive function and a strong correlation
between magnitude of IDO expression and suppression of T cell
proliferation has been discovered [16].
PGE-2 has been highlighted as a central mediator of the
inhibitory effects of MSCs upon immune cells [17]. It has been
discovered [18,19] that, in response to pro-inﬂammatory media-
tors, MSCs secrete PGE-2 which requires intimate association or
cell to cell contact to bind to the EP2 and EP4 receptors of resident
macrophages. The binding of PGE-2 to host macrophages drives the
transition of these cells from their classical M1,  pro-inﬂammatory
phenotype towards an M2,  anti-inﬂammatory phenotype in which
these macrophages secrete anti-inﬂammatory mediators, includ-
ing IL-10 and IL-1 receptor agonist [19].
The hypoxic culture and preconditioning of hMSCs, in which
≤1% O2 is commonly used, has been found to induce the over-
expression of VEGF, an established pro-angiogenic factor [20–25].
A number of these studies have identiﬁed VEGF as the most criti-
cal factor responsible for the angiogenic properties of MSCs in vivo
[21–26]. Furthermore, the expression of this protein by MSCs has
also been associated with an anti-apoptotic effect upon host cells,
improving cell survival in a number of studies [21,24].
Therefore, it is clear that the expression of PGE-2, IDO and VEGF
are crucially important for the anti-inﬂammatory, immune modu-
latory, angiogenic and anti-apoptotic MSC  modes of action. Thus,
the measurement of these paracrine factors in the present study,
after hMSC priming, may  allow for the determination and compari-
son of the functional activity of hMSCs cultured using either manual
or automated process steps.
2. Materials & methods
2.1. hMSC culture
2.1.1. CompacT SelecT preparation & calibration
Prior to the performance of any automated protocol on the TAP
Biosystems’ CompacT SelecT platform, the machine was  prepared
for use by ensuring a sufﬁcient number of pipette tips were loaded,
sufﬁcient new T175 ﬂasks were available, that adequate volume
of reagents were loaded aseptically, and that the required sterile
plastic tubing (Watson-Marlow Pumps, Falmouth, UK) was con-
nected to allow for reagents to be pumped using the peristaltic
pump system.
In order to ensure that the required volumes of reagent are dis-
pensed throughout each protocol, a calibration step is performed
prior to the performance of each CompacT SelecT protocol. Brieﬂy,
the plastic tubing was  primed and a small volume of reagent was
dispensed into a BD FalconTM T175 tissue culture ﬂask (BD Bio-
sciences, San Jose, USA). The ﬂask was  then exported and the
l Engin
c
o
T
i
s
2
f
L
l
w
r
t
t
i
f
r
t
t
U
(
B
m
p
t
ﬂ
t
w
p
m
a
C
w
L
a
i
9
L
E
c
c
s
c
2
v
i
(
t
m
t
w
b
m
a
ﬂ
C
f
g
ﬂ
s
a
tP.R.T. Archibald et al. / Biochemica
ontents were weighed on digital scales to determine the volume
f reagent dispensed, assuming that 1 mL  of reagent weighs 1 g.
his value can then be entered into the CompacT SelecT software
n order to calibrate the peristaltic pump system, which adjusts the
ubsequent dispensing steps accordingly.
.1.2. Creation of a hMSC working bank
The hMSCs utilised in the present study were previously derived
rom bone marrow mononuclear cells (BM-MNCs), purchased from
onza (Basel, Switzerland), by colleagues in the Centre of Bio-
ogical Engineering (Loughborough, UK). Brieﬂy, the BM-MNCs
ere plated on tissue culture plastic and non-adherent cells were
emoved through culture over 2 passages. The isolated hMSCs were
hen cryopreserved (P0), and one vial of these cells was  utilised as
he source material for the generation of the hMSC working bank
n the present study.
The initial hMSC vial (P0), containing 1 × 106 cells, was removed
rom cryostorage, thawed, centrifuged, and the supernatant aspi-
ated in order to remove the cryopreservant. The cells were
hen re-suspended in pre-warmed DMEM high glucose (HG) Glu-
aMAX (Life Technologies, Thermo Fisher Scientiﬁc, Waltham,
SA) supplemented with 10% Qualiﬁed Fetal Bovine Serum (FBS)
Gibco®, Life Technologies) and manually seeded into a BD FalconTM
arcoded T175 ﬂask (BD Biosciences). Subsequently, complete
edium exchanges were performed every 3 days after seeding or
assage. Once 80% conﬂuency of the culture had been conﬁrmed
hrough visual examination, after approximately 6 days, the mother
ask was manually passaged into four new daughter ﬂasks. Once
he 4 daughter ﬂasks had reached 80% conﬂuency, each of the ﬂasks
ere imported into the CompacT SelecT automated cell culture
latform and passaged into 16 granddaughter ﬂasks using an auto-
ated passage protocol. Once these granddaughter ﬂasks reached
pproximately 80% conﬂuency, the ﬂasks were exported from the
ompacT SelecT and manually prepared for cryopreservation by
ashing and dissociating cells. The enzyme (Trypsin 0.05% EDTA,
ife Technologies) was then neutralised with complete medium
nd the suspension was centrifuged (276 RCF × 5 min) in order to
solate a cell pellet. Finally, the cell pellet was re-suspended in
0% FBS and 10% dimethyl sulfoxide (DMSO) (Sigma Aldrich, St
ouis, USA) and 2 × 106 cells were transferred into each cryovial.
ach cryovial was stored at −80 ◦C for 24 h, in a Mr.  Frosty freezing
ontainer (Thermo Fisher Scientiﬁc), before being transferred into
ryostorage. The cells generated for this working cell bank repre-
ent ‘Baseline’ hMSCs (P2), to which the hMSCs cultured utilising
entrifugation or non-centrifugation process steps were compared.
.1.3. hMSC centrifugation culture method
For each of the four experimental runs, one cryopreserved hMSC
ial (2 × 106 cells) was thawed in a 37 ◦C water bath, re-suspended
n DMEM HG GlutaMAXTM supplemented with 10% FBS, centrifuged
400 RCF × 5 min), and the supernatant aspirated in order to remove
he cryopreservant. The cells were then re-suspended in complete
edium, transferred into a barcoded T175 ﬂask and imported into
he CompacT SelecT, at which point an automated seeding protocol
as initiated, during which 7 × 105 cells were seeded into a new
arcoded T175 ﬂask (P3). Conﬂuency was examined daily using
icroscopy and a complete medium exchange was  performed 72 h
fter seeding and each passage. Once the culture reached 80% con-
uency, after approximately 6 days, a hMSC pre-centrifugation
ompacT SelecT automated protocol was utilised to detach the cells
rom the mother ﬂask and to obtain cell count, viability and aggre-
ation data using the Cedex automated cell counter. The mother
ask was then “borrowed” from the CompacT SelecT and the cell
uspension was centrifuged (400 RCF × 5 min) in order to isolate
 cell pellet. After the cell pellet was re-suspended in fresh cul-
ure medium, the cells were transferred back into the mother ﬂaskeering Journal 108 (2016) 69–83 71
which was  then imported back into the CompacT SelecT and a
hMSC post-centrifugation automated protocol was performed in
order to obtain cell count, viability and aggregation data and to
passage the mother ﬂask at a 1:4 split ratio, seeding four new
daughter T175 ﬂasks with 7 × 105 cells (P4). Once each of the 4
daughter ﬂasks reached approximately 80% conﬂuency, the pre-
and post-centrifugation protocols were again utilised in order to
passage the 4 daughter ﬂasks into 16 new granddaughter ﬂasks
(P5) and to obtain cell count, viability and aggregation data. Once
the granddaughter ﬂasks reached approximately 80% conﬂuency,
all 16 ﬂasks were pooled, using a hMSC pool automated protocol,
and the cells were isolated using centrifugation (400 RCF × 5 min),
re-suspended in cryopreservation medium (90% FBS & 10% DMSO)
and cryopreserved in a sufﬁcient number of cryovials.
2.1.4. hMSC non-centrifugation culture method
For each of the four experimental runs, similar thawing,
centrifugation, and re-suspension processes as in the hMSC cen-
trifugation culture method were utilised in order to remove the
cryopreservant and suspend the cells in complete culture medium.
Once again, the cells were transferred into a barcoded T175 ﬂask
and imported into the CompacT SelecT, at which point an auto-
mated seeding protocol was again initiated, and 7 × 105 cells
were seeded into a new barcoded T175 ﬂask (P3). Similarly to
the centrifugation method, conﬂuency was  examined daily using
microscopy and a complete medium exchange was performed
72 h after seeding and each passage. However, once the cells
reached 80% conﬂuency, after approximately 6 days, a hMSC non-
centrifugation protocol was  utilised, in which an enzyme pour-off
step was  utilised to dissociate the cells. During this dissociation
process, Trypsin EDTA was  applied, ensuring that the entire sur-
face of the T175 ﬂask is coated, and was  immediately poured off,
leaving only a residual layer of enzyme coating the ﬂask which
was then incubated in order to dissociate the cells. The hMSC
non-centrifugation protocol also obtained cell count, viability and
aggregation data and passaged the mother ﬂask into four daugh-
ter ﬂasks, seeding each with 7 × 105 cells (P4). Once each of the 4
daughter ﬂasks reached approximately 80% conﬂuency, the non-
centrifugation protocol was again utilised to passage each of the 4
ﬂask into 16 new granddaughter ﬂasks (P5) and obtain cell count,
viability and aggregation data. Finally, once each of the 16 grand-
daughter ﬂasks reached approximately 80% conﬂuency, all 16 ﬂasks
were pooled and the cells were isolated using centrifugation (400
RCF × 5 min), re-suspended in cryopreservation medium (90% FBS
& 10% DMSO) and cryopreserved in a sufﬁcient number of cryovials.
2.2. Surface marker expression
2.2.1. Loughborough University ﬂow cytometry analysis of hMSCs
cultured using CompacT SelecT automated centrifugation &
non-centrifugation process steps
Baseline (P2), centrifugation (P5), and non-centrifugation (P5)
hMSCs were thawed, seeded in separate T175 ﬂasks at a den-
sity of 4 × 103 cells/cm2 (7 × 105 cells/T175 ﬂask), and cultured, as
described previously, until they reached approximately 80% con-
ﬂuency (∼6 days). Once conﬂuent, the cells were dissociated, using
trypsin EDTA, a cell count was performed, and 1 × 105 cells were
plated per well in the relevant number of wells of a 96-well plate.
The cells were prepared for ﬂow cytometry using the relevant
reagents, antibodies and isotype controls from the BD StemﬂowTM
kit (BD Biosciences) as indicated in the manufacturer’s instruc-
tions. Each sample, plated with the relevant antibody cocktail,
antibody drop-in, or isotype control, was  repeated in triplicate. To
determine the immunophenotype of baseline, centrifugation, and
non-centrifugation hMSCs, multicolour ﬂow cytometry was per-
formed utilising positive and negative antibody cocktails for the
7 l Engineering Journal 108 (2016) 69–83
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Fig. 1. TAP Biosystem’s CompacT SelecT automated cell culture platform (TAP
Biosystems, Royston, UK).2 P.R.T. Archibald et al. / Biochemica
rimary CD markers that constitute the ISCT minimum criteria for
MSCs [3]. This included the positive expression of CD105, CD90,
D73 and CD44; and the negative expression of CD34, CD45, CD11b,
D19 and HLA-DR. The utilisation of pre-conjugated antibody
ocktails allowed for multiparameter analysis of surface marker
xpression at the single cell level. This method has been previously
alidated by colleagues at Loughborough University [27].
The hMSC samples were analysed on the BD FACSCanto II (BD
iosciences) which was operated using the FACSDiva software ver-
ion 6.1.3. For analysis, the ﬂow cytometry data was  exported in
CS 3 format and analysed using FlowJo software v10.
.3. Comparability in surface marker expression
.3.1. LGC hMSC culture using manual centrifugation &
on-centrifugation process steps for ﬂow cytometry analysis
P2 hMSCs (‘Baseline’, Working Bank) were transferred from
oughborough University to LGC. From P3 to P5, hMSCs were cul-
ured and expanded using manual protocols mimicking that of
he manual (centrifugation) and automated (non-centrifugation)
rocess steps performed at Loughborough University. In order to
anually perform both the centrifugation and non-centrifugation
ulture processes, the automated protocols, as described previ-
usly, were replicated as closely as possible, with similar reagents
nd process steps, but without the use of the CompacT SelecT
utomated cell culture platform. In contrast to the automated pro-
esses, cell counting was performed using the Vi-Cell XR (Beckman
oulter, Brea, USA) during both the manual centrifugation and non-
entrifugation processes, rather than using the Cedex automated
ell counter. P5 cells were pooled at 1 × 106 cells per ml  in DMEM
ith 10% FBS and 10% DMSO and cryopreserved in liquid nitrogen.
.3.2. LGC ﬂow cytometry analysis of hMSCs cultured using
anual centrifugation & non-centrifugation process steps
Brieﬂy, pre-banked hMSCs (P5) were analysed directly after
ryopreservation in liquid nitrogen and prepared by thawing,
emoving the cryoprotectant, and ﬁxing in 1× cell ﬁxation buffer
BD Biosciences), incubating in Fc blocking reagent (BioLegend,
an Diego, USA). Next, 2 × 105 cells were incubated with the
elected group of antibody/isotype control cocktails in staining
uffer (BioLegend) and washed before being transferred into 5 ml
olystyrene round-bottom ﬂow cytometry tubes (BD Biosciences).
To identify the correct phenotypic pattern of BM isolated hMSCs,
mmunophenotyping was  performed by ﬂow cytometry utilising
he most commonly used monoclonal antibodies based upon the
iterature (see Fig. 3 and Appendix 1.1 of Supplementary material).
he expression level of different surface markers was analysed by
irect immunolabeling approach. Staining was performed on pas-
age 5 cells from each condition (post-cent and non-cent) using the
elected group of antibody cocktails with the corresponding isotype
Fig. 2. Process diagram illustrating the differences between the CompacT SelecT manualcontrols (Fig. 3). This enabled target cells to be labelled and ana-
lysed on the ﬂow cytometer for the designated group of antibodies
simultaneously.
hMSC samples were analysed on the BD FACSCanto II (BD Bio-
sciences), operated through the FACSDiva software version 6.1.3,
and exported the data in FCS 3 format for analysis using FlowJo
software v10.
2.4. Cell line authentication (CLA) & short tandem repeat (STR)
proﬁling
STR proﬁling was performed by LGC Standards (Teddington,
UK) through their commercially available cell line authentica-
tion (CLA) service. Samples were prepared for transport and CLA
analysis by following the protocol provided by LGC Standards.
One cryovial of hMSCs from the Working Cell Bank (Baseline, P2)
(2 × 106 cells), 1 cryovial of post-centrifugation hMSCs (P5) (2 × 106
cells), and 1 cryovial of non-centrifugation hMSCs (P5) (2 × 106
cells) were removed from cryostorage, thawed and microfuged
(73 RCF × 5 min). The supernatant was then aspirated and a PBS
wash was applied, in order to remove any cryopreservant. The
samples were again microfuged and the supernatant was  again
aspirated in order to isolate the cell pellets. Finally, the samples
were re-suspended in 400 L of transport buffer, provided by LGC
Standards, which lysed the cells and preserved the gDNA. The sam-
ples were then packaged and sent to LGC Standards, where the CLA
analysis was  undertaken and the STR proﬁles for each sample were
compared.
 (centrifugation) and automated (non-centrifugation) hMSC culture process steps.
P.R.T. Archibald et al. / Biochemical Engineering Journal 108 (2016) 69–83 73
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egative (−) markers. Pre-conjugated antibodies were selected to generate four gro
.5. Paracrine functionality assays
.5.1. hMSC pre-treatment
Three cryovials of hMSCs from the Working Cell Bank (Baseline,
2) (2 × 106 cells), three cryovials of post-centrifugation hMSCs
P5) (2 × 106 cells), and three cryovials of non-centrifugation
MSCs (P5) (2 × 106 cells) were thawed and 1 × 106 cells from
ach cryovial were seeded into nine separate T175 ﬂasks with
MEM HG GlutaMAXTM with 10% FBS. These nine T175 ﬂasks were
ivided into three groups of three T175 ﬂasks, with each group
ontaining one ﬂask from each of the baseline, post-centrifugation,
nd non-centrifugation conditions. The three groups consisted
f ‘inﬂammatory pre-treatment’ (IN-PT), ‘hypoxic pre-treatment’
HY-PT), and no treatment (NT) groups. After three days of cul-
ure, a media exchange was performed for each of the 9 ﬂasks. The
edium was aspirated from all hMSC ﬂasks, and the ﬂasks in each
f the groups were speciﬁcally pre-treated:
The IN-PT hMSCs were treated with DMEM HG GlutaMAXTM with
10% FBS, as well as 10 ng/mL IFN- (Sigma–Aldrich) and 15 ng/ml
TNF- (Sigma–Aldrich) for a further 72 h. These conditions were
selected based upon the ISCT guidelines for immunological char-
acterisation of MSCs [5].
The HY-PT hMSCs were treated with DMEM HG GlutaMAXTM with
10% FBS, which had been pre-conditioned at 1% O2 overnight,
and were incubated at 37 ◦C at 1% O2 for a further 48 h.
These conditions were selected based upon established hypoxic
hMSC preconditioning methods [28,22,29,25]. Chacko et al. [25]
demonstrated, through hypoxic pre-treatment for 72 h, that VEGF
expression was greatest after 48 h of pre-treatment.
The NT hMSCs were treated with DMEM HG GlutaMAXTM with
10% FBS and incubated at 37 ◦C at 5% CO2 for a further 72 h.
After the hMSC populations were exposed to either the IN-PT,
Y-PT or NT conditions, the conditioned medium from each ﬂask
as collected and stored at −80 ◦C.
.5.2. Kynurenine quantiﬁcation & IDO activity measurement
The enzyme indoleamine 2,3-dioxygenase (IDO) converts tryp-
ophan to kynurenine, and the following assay was  used to
hotometrically determine the concentration of kynurenine in
nﬂammatory pre-treated (IN-PT) or no treatment (NT) conditioned
edium samples from each of the baseline, post-centrifugation,
nd non-centrifugation hMSC groups. This assay has been success-
ully utilised in a number of previous studies in order to quantify
DO activity for a number of cell types, including hMSCs [30–33].
150 L of each of the conditioned medium samples, as well
s a fresh DMEM with 10% FBS sample, were pipetted into sep-
rate 5 mL  Eppendorf tubes (Eppendorf, Hamburg, Germany) and
0 L of 30% trichloroacetic acid (TCA) (Sigma–Aldrich) was added
o each. Each of the samples was then incubated for 15 min  at
0 ◦C and microfuged at 10,000 g for 5 min  in order to hydrolyse
-formylkynurenine to kynurenine. 75 L of the supernatant from
ach of the samples was transferred to a 96-well plate. A serial dilu-
ion of 100 m kynurenine solution (Sigma–Aldrich) was used as
 standard (100 m to 0 m)  to allow for the generation of a stan-dies were categorised in groups as “generic”, “stress”, “MSC positive (+)” and MSC
f antibody cocktails.
dard curve. 75 l of Ehrlich’s reagent (1% p-dimethylbenzaldehyde
in glacial acetic acid) (Sigma–Aldrich) was added to each well and
the plate was incubated for 10 min  at room temperature. Finally,
the ﬂuorescence of each well was determined by measuring the
absorbance at 492 nm.  Each sample was measured in duplicate
and a repeat of the assay was  performed in order to increase the
reliability of the data. Sample data was normalised against the aver-
age absorbance of two culture medium (DMEM HG GlutaMAXTM
with 10% FBS) blanks. Culture medium normalised values were
then standardised utilising the kynurenine standard curve and the
average values were then generated.
2.5.3. PGE-2 quantiﬁcation
The prostaglandin E2 enzyme-linked immunosorbant assay
(ELISA) was  performed following the manufacturer’s direc-
tions (Life TechnologiesTM, InvitrogenTM Novex® Prostaglandin
E2Human ELISA Kit). All buffers, tracers and antibodies were pre-
pared as described in the manufacturer’s directions. Prostaglandin
E2 standard was prepared at the recommended concentrations,
however, culture medium rather than Tris buffer was  used for the
dilution of the standard curve. This is recommended in the man-
ufacturer’s directions if performing an assay of culture medium
samples. Two  blank wells, two non-speciﬁc binding wells, three
maximum binding wells, one total activity well, sixteen standard
wells (8 standards in duplicate), and eighteen sample wells (6 wells
in triplicate) were prepared as indicated in the manufacturer’s
guidelines. After incubation for 90 min in the dark, on an orbital
shaker, the absorbance was measured using a plate reader at a
wavelength of 410 nm.
2.5.4. VEGF quantiﬁcation
The VEGF enzyme-linked immunosorbant assay (ELISA)
was performed following the manufacturer’s directions (Life
TechnologiesTM, InvitrogenTM Novex® Human VEGF ELISA Kit). All
buffers, tracers and antibodies were prepared as described in the
manufacturer’s directions. VEGF standard was diluted in standard
diluent buffer and the manufacturer’s directions were followed in
order to generate a standard curve. Two chromogen blank wells,
two zero wells, sixteen standard wells (8 standards in duplicate),
and eighteen sample wells (6 wells in triplicate) were prepared as
indicated in the manufacturer’s guidelines. After a ﬁnal incubation
of 30 min  at room temperature, in the dark, the absorbance was
measured using a plate reader at a wavelength of 450 nm. VEGF
concentration in each sample was  determined by plotting the
absorbance of samples against the VEGF standard curve. In order
to correct for the 1:2 dilution of samples performed during the
assay, VEGF concentrations of each sample were multiplied by 2.
2.6. Statistical analyses
Experimental data regarding the viable cell density, viable cell
yield, and viability of pre-centrifugation, post-centrifugation and
non-centrifugation hMSCs within each passage was assessed using
one-way analysis of variance (ANOVA) multiparameter analysis,
utilising the IBM SPSS statistical software (Armonk, USA), to deter-
mine signiﬁcant differences. One-way ANOVAs were also used
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o assess the signiﬁcance of differences in the standard devi-
tions (SD) of the viable cell densities, viable cell yields, and
iabilities of hMSC pre-centrifugation, post-centrifugation, and
on-centrifugation samples, in each of the four batches, from the
econd passage. Two-way ANOVAs were used to assess signiﬁcant
ifferences in the viable cell density, viable cell yield, and viability
f pre-centrifugation, post-centrifugation and non-centrifugation
MSCs across all passages. Finally, One-way ANOVAs were used
o determine the signiﬁcance of any differences in the kynurenine,
GE-2, and VEGF concentrations of untreated and pre-treated base-
ine, post-centrifugation, and non-centrifugation hMSCs in their
espective assays. The cut-off value for statistical signiﬁcance (p)
as set at 0.05. Tukey’s honest signiﬁcant difference (HSD) Post-
oc tests were used to perform multiple comparisons of the hMSC
rowth and paracrine functionality data.
ig. 5. Exemplar scatter plots of Loughborough University multicolour ﬂow cytometric ana
o-expression of ‘Baseline’ hMSCs (P2).on-centrifugation (NC) (B) day 3 morphology.
3. Results & discussion
3.1. Morphology
One basic, preliminary method of characterising a cell popula-
tion is through visual examination of a culture under an inverted
light microscope with a digital camera attachment (Nikon Eclipse
Ts100, Nikon, Tokyo, Japan). Although, this method does not give
an accurate or quantiﬁable measure of the identity or charac-
teristics of the cells, it can be used as a rudimentary method of
verifying that the cells have not differentiated or undergone any
substantial transformations. Fig. 4 demonstrates that no difference
in morphology was  observed between hMSCs cultured utilising
manual or automated process steps, and that both hMSC popula-
tions exhibited a spindle shaped, ﬁbroblast-like morphology. This
lysis. Scatter plots presented demonstrate the positive and negative surface marker
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ean  percentage expression level of surface markers of BM-MSC cells (P5), and err
ould suggest that neither the centrifugation step in the manual
rocess, nor the trypsin carryover in the automated process, had a
ubstantial effect upon the morphology of the hMSCs.
.2. Surface marker expression
The ISCT minimal criteria for the phenotypic expression of
MSCs indicates that ≥95% of the cell population should express
D105, CD73 and CD90, and that ≤2% of the cell population should
xpress CD45, CD34, CD11b, CD19 or HLA-DR [3]. Differences in
he expression of hMSC surface markers, between automated and
anually-replicated passage protocols, were examined by compar-
ng ﬂow cytometry analyses performed at two laboratories using
ither BD Biosciences StemﬂowTM kit (Loughborough University)
r in-house prepared antibody cocktails (LGC).
As demonstrated in Fig. 5, the multicolour analysis performed at
oughborough University allowed for the demonstration of the co-
xpression of multiple hMSC positive markers, as well as the lack
f co-expression of multiple negative markers and haematopoietic
ntigens, on single cells. This method conforms to that recom-
ended in the ISCT minimal criteria [3]. Furthermore, no signiﬁcant
ifference in positive or negative expression was  observed between
MSCs cultured utilising alternative process steps, and between
arly (P2) and late (P5) passage hMSCs, with all populations
xpressing ≥95% positive marker expression and ≤2% negative
arker expression (see Appendices 2.1 and 2.2 of Supplementary
aterial).
.3. Comparability in surface marker expression
The immunophenotype of hMSCs cultured and analysed by LGC
et  the majority of hMSC surface marker expression criteria, in
oncordance with Loughborough University’s results (see Fig. 6 and
ppendix 3.1 of Supplementary material). Signiﬁcant expression
f the primary hMSC positive markers (CD105, CD73 and CD90)
as found. However, both CD105 and CD146 expression was lower
han expected in the LGC analysis, with CD105 expression falling
elow the threshold set within the ISCT minimal criteria. The low
xpression of CD146 (MCAM) may  reﬂect heterogeneity in the
xpression of this marker between individual donors. Alternatively,
ower CD146 expression may  reﬂect the later passage number ofst-cent) and non-centrifugation (non-cent) bone marrow-derived hMSCs (P5). The
s reﬂecting technical variation (SD, n = 3) are plotted.
hMSCs used for ﬂow cytometry analysis as this marker has been
associated with cells that possess a shorter doubling time [34].
The typical hMSC negative markers CD45, CD11b and HLA-DR
conformed to the ISCT minimal criteria, with expression observed
at <2%. However, discordant CD34 expression was observed
between the two  laboratories, with higher percentage expression of
CD34 in LGC’s analysis compared to that of Loughborough Univer-
sity. There is signiﬁcant uncertainty regarding the CD34 expression
of hMSCs which has been identiﬁed as a hMSC marker in adult adi-
pose tissue [35]. Although CD34 negativity is outlined in the ISCT
minimal criteria, further research on these cells has indicated that
the lack of CD34 expression may  be an in vitro artefact and these
cells may  in fact be CD34+ in their in vivo niche [36].
In addition to the ISCT minimal phenotypic criteria for the
identiﬁcation of hMSCs, it has been identiﬁed that these cells can
stain positive for a number of surface markers, including CD9,
CD29, CD44, CD63, CD99, CD106, CD146 and negative for CD14,
CD34, CD45 and CD133 [37]. LGC ﬂow cytometry analysis also
identiﬁed that a high proportion of hMSCs expressed generic and
stress-related surface markers CD9, CD29, CD63, as well as partial
expression of CD146 and CD98 (Fig. 6).
The LGC ﬂow cytometric analysis of hMSCs, cultured using either
the manually replicated centrifugation or non-centrifugation pro-
cess steps over two passages, revealed a similar level of surface
marker expression in both conditions. Finally, the inter-laboratory
comparison of hMSC surface marker expression, suggests that the
utilisation of alternative methods of analysis may  be a source
of variability in the results obtained from ﬂow cytometry. This
highlights the need for standardisation and calibration of ﬂow
cytometry methodologies and equipment. However, differences in
culture protocols between sites, with LGC manually replicating the
automated process steps, may  have also inﬂuenced this variation
in surface marker expression.
3.4. Cell line authentication (CLA) analysis & short tandem repeat
(STR) proﬁlingShort tandem repeat (STR) proﬁling is a method used to amplify
and compare speciﬁc loci on the DNA of multiple cell populations,
and is often used in forensic analysis [38,39]. An STR is a unit of
multiple nucleotides which are repeated many times in sequence
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long the length of a DNA strand, and by counting the number of
hese repeating units at speciﬁc loci within the DNA, an individual
roﬁle of the sample can be generated. The STR proﬁle analysis used
n this study was provided by LGC Standards as part of their cell
ine authentication (CLA) service, and this is used to measure the
ifference in STRs at 16 loci within the genome between samples.
he output of each of these analyses is an electropherogram (EPG)
llustrating the relative expression of STRs at each loci, as indicated
y peaks in ﬂuorescence on the EPG.
In the present study, STR proﬁles were generated for each of the
aseline, post-centrifugation and non-centrifugation samples, and
he post- and non-centrifugation EPGs were compared to that of the
aseline in order to determine whether the manual or automated
rocess steps had any signiﬁcant effect upon the hMSC STR pro-
le. Fig. 7 demonstrates that no signiﬁcant difference was observed
etween the short tandem repeat (STR) proﬁles of the baseline,
ost-centrifugation and non-centrifugation hMSCs, and that sam-
le each expressed peaks in STRs at the same loci.
However, comparison of the EPGs of the baseline, non-
entrifugation, and post-centrifugation hMSC samples highlights
ossible differences in peak sizes and levels of STR expression,
hich may  therefore indicate differences in the number of copies
f the STR at each locus. However, it is also apparent that varia-
ions in ﬂuorescence may  occur between experimental runs, due
o differential ampliﬁcations of the alleles or primer-binding site
utations [40], and therefore examining differences in peak sizes
ay  be redundant. Therefore, variations in peak size between hMSC
amples provided in this experiment were not considered to rep-
esent a signiﬁcant change in the identity of a cell sample and each
f the samples were considered to have identical STR proﬁles.
.5. Viable cell yield
The chart above (Fig. 8), illustrates the average viable hMSC
ield of centrifugation and non-centrifugation ﬂasks from all four
atches over two passages, as well as the viable cell number prior
o seeding each of the mother ﬂasks for each experimental run.
hese results demonstrate that no signiﬁcant difference between
iable hMSC yield obtained utilising pre-centrifugation, post-
entrifugation, and non-centrifugation process steps was  observed
n each passage or across all passages. Therefore, it can also be
oncluded that the presence of residual trypsin carried over dur-ation (C), electropherogram short tandem repeat (STR) proﬁle (LGC Standards).
ing the automated dissociation process step had no detrimental
effect upon the number of obtainable cells compared to when this
residual dissociation agent was  removed using a manual centrifu-
gation process step, commonly utilised in traditional cell culture
protocols.
Furthermore, Fig. 8 may  indicate a decrease viable hMSC yield
after the process of centrifugation. This could suggest that that
further optimisation of the centrifugation step is required, as
excessively high relative centrifugal force (RCF) may  induce cell
death and insufﬁcient RCF may  not create an adequate cell pellet.
However, statistical analysis does not support this trend and no sig-
niﬁcant difference between pre- and post-centrifugation viable cell
yield was observed (p = 0.524). Furthermore, the RCF and duration
of centrifugation utilised in the present study are often recom-
mended in industrial cell culture protocols.
Additionally, the results of the present study indicate that the
viable cell yields in P4 were signiﬁcantly greater than those in P5
(p = 0.036), regardless of whether the manual or automated pro-
cess steps were utilised. This implies that the growth rate of the
hMSCs decreased over two  passages, which supports the ﬁndings
of previous investigations [9]. This may  suggest that the cells had
begun to enter senescence over the duration of their culture over
two passages, and thus their growth rate began to decrease.
Finally, although no apparent difference in viable cell yield
between hMSCs cultured utilising manual or automated process
steps, in each batch over two  passages, was  determined, the stan-
dard deviations data (Fig. 8) indicates that greater variability in
viable cell yield may  have been observed in non-centrifugation
hMSC samples compared to pre- or post-centrifugation hMSC sam-
ples. This may  suggest that the utilisation of the non-centrifugation
process step produces less consistent viable cell yields compared to
when the centrifugation process step is employed and samples are
measured either pre- or post-centrifugation. However, no signiﬁ-
cant difference between the standard deviations of the viable hMSC
yield data generated using each of the process steps was  found, and
therefore, it cannot be concluded that any difference in variability
between process steps was observed.
Although, the viable cell yield data illustrates a non-signiﬁcant
trend for greater variation when utilising the non-centrifugation
process step compared to the centrifugation process step using the
CompacT SelecT platform, it is likely that a fully automated cell
culture process will be more consistent in comparison to a fully
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utliers are plotted and standard deviations are shown as error bars.
anual cell culture process. A reduction in variability is a typical
utcome of the automation of manual cell culture processes and
as been demonstrated in a number of previous studies [41,8,10].
It is likely that any increased variability within the automated
rocess step can be attributed to differences between the mixing
teps utilised in the manual and automated process steps. During
he manual centrifugation process step, after the cells have been
entrifuged, the cells are re-suspended in fresh culture medium
nd thoroughly mixed to ensure that a single cell suspension is
enerated. However, during the automated dissociation process
tep, the cell suspension is re-suspended using a deﬁned number
f automated mixing steps, which may  not have been sufﬁcient
o generate an evenly mixed single cell suspension for each hMSC
opulation. This failure to generate a homogenous single cell sus-
ension in ﬂasks undergoing a passage is likely to have created
ifferences in the number of cells seeded into new daughter ﬂasks.
lso, the inadequate mixing of hMSC suspensions when utilising
he non-centrifugation process step may  have also led to sampling
rocess errors. Without sufﬁcient re-suspension of hMSC popula-
ions, it is likely that heterogeneity in cell counts would exist within
 suspension, when multiple samples are taken from within a sin-
le suspension. Additionally, this variability may also be observed
etween suspensions, when a single sample is taken from multiple
uspensions, and this inconsistency may  be due to differences in
ell aggregation, settling and adherence. Therefore, further optimi-
ation studies may  be required to develop a protocol with sufﬁcient
ixing steps to generate a single cell suspension and to allow for
ore consistent hMSC seeding.
.6. Live cell aggregate size
In the chart above (Fig. 9), the average number and size of viable
MSC aggregates from the pre-, post- & non-centrifugation sam-
les in batches 1–4, across two passages, are plotted. This data
emonstrates that after centrifugation, an increase in the num-
er of cells present in smaller aggregate sizes occurred. This would
mply that the centrifugation process step may  have reduced the
arger aggregates of cells into smaller aggregates or into single
ells, which is often reported with mammalian cells [42]. How-
ver, the lack of a greater number of cells in larger aggregates in
he pre-centrifugation samples may  not support this conclusion.
lthough, the centrifugation process step may  reduce the obtain-
ble viable cell yield, when the standard deviations of the pre- andll four batches for both the ﬁrst (n = 4) and second (n = 16) experimental passages.
post-centrifugation viable cell yields are compared, it appears that
it may  reduce the variability in the cell count. This may  be attributed
to the increased number of small aggregates observed after the cen-
trifugation process step which may  therefore lead to more reliable
cell counts and more consistent seeding of daughter ﬂasks.
It is also apparent that no difference in live cell aggregate size
was observed when either the centrifugation or non-centrifugation
process steps were utilised. However, the larger standard devia-
tions in live cell aggregate size after the non-centrifugation process
step may  support the viable cell yield data and demonstrates the
variability observed when the non-centrifugation process step was
utilised.
3.7. Viability
The ﬁgure above (Fig. 10) summarises the mean viabili-
ties for hMSC samples after seeding, pre-centrifugation, post-
centrifugation, and non-centrifugation, across all four batches, and
over two passages. These results indicate that no signiﬁcant dif-
ference in the viability of hMSC cultures was observed between
centrifugation and non-centrifugation cell culture process steps,
which would therefore suggest that the enzyme carryover in the
non-centrifugation process step had no detrimental effect upon
cell viability. It is also apparent that no signiﬁcant difference
between pre-centrifugation and post-centrifugation hMSC viability
was demonstrated, and therefore that the process of centrifugation
had no signiﬁcant effect upon hMSC viability. Furthermore, no sig-
niﬁcant difference in the variation of hMSC was  observed between
process steps or passages, and this variation was  approximately 4%
(±2%) viability in each group.
3.8. Paracrine functionality assays
3.8.1. Kynurenine quantiﬁcation & IDO activity measurement
The expression of IDO by hMSCs has been associated with the
immunosuppressive properties of these cells, and this enzyme has
been found to be one of the key bioactive factors responsible for the
suppression of T, B, dendritic and NK cells [13,14,16]. Waterman
et al. [43] discovered that, after toll-like receptor 3 (TLR3) priming,
hMSCs exhibited an immunossupressive phenotype during which
these cells demonstrated an increased IDO expression which acted
to suppress T lymphocyte activation. Meisel et al. [30] previously
described the mechanism through which the hMSC secreted IDO
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nhibits T-cell activation, with their ﬁndings indicating that the
xpression of IDO, which converts tryptophan to kynurenine, by
MSCs signiﬁcantly inhibited allogeneic T-cell responses, that the
ddition of tryptophan restored T-cell proliferation, and therefore
hat it is the IDO-mediated catabolism of tryptophan to kynurenine
hat is responsible for the inhibitory effects of hMSC secreted IDO
pon T-cell activity. Also, more recently, Francois et al. [44] deter-
ined that tryptophan inhibition abolished hMSC suppression of T
ell proliferation, that the level of IDO expression was  correlated
o hMSC immunosuppressive potential, and that hMSC secreted
DO caused monocytes to differentiate into immunosuppressive
acrophages.
However, it is generally accepted that hMSCs must be stimu-
ated by pro-inﬂammatory cytokines, particularly IFN-, in order
o upregulate IDO expression [45,30]. The data from the present
tudy, in which kynurenine concentration was measured photo-
etrically, supports this hypothesis and it was determined that
ntreated hMSCs did not constitutively express IDO and that
re-treatment with inﬂammatory cytokines, speciﬁcally IFN-
nd TNF-, was required to stimulate the expression of IDO byg, pre-centrifugation, post-centrifugation, and after the non-centrifugation process
rd deviations are shown as error bars.
hMSCs. As untreated hMSCs did not express IDO, and therefore
did not induce signiﬁcant breakdown of tryptophan or the resul-
tant increase in kynurenine concentration, no signiﬁcant difference
between untreated baseline, centrifugation or non-centrifugation
hMSCs was  observed. Furthermore, as inﬂammatory pre-treatment
signiﬁcantly increased IDO activity in all hMSC samples, the results
of the present study indicate that hMSCs cultured utilising either
manual or automated process steps expressed IDO in response to
IFN- stimulation, as is typical of hMSCs [12].
The results of this IDO assay may also indicate a non-
signiﬁcant trend for the kynurenine concentration in pre-treated
Centrifugation (p = 0.763) and non-centrifugation (p = 0.273) hMSC
conditioned medium to be reduced compared to that of pre-
treated Baseline hMSC conditioned medium, which would suggest
that the IDO activity of the hMSCs decreased over two pas-
sages, regardless of the process step utilised. Additionally, Fig. 11
also illustrates a non-signiﬁcant trend for a greater kynurenine
concentration in inﬂammatory pre-treated centrifugation hMSC
conditioned medium compared to that of inﬂammatory pre-treated
non-centrifugation hMSC conditioned medium (p = 0.943), which
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ould suggest that the IDO activity of pre-treated hMSCs cul-
ured utilising the centrifugation process step was greater than
hat of pre-treated hMSCs cultured utilising the non-centrifugation
rocess step. However, given the large standard deviation of the
aseline hMSC conditioned medium samples and the lack of signif-
cance of these trends, further optimisation of the kynurenine assay
s required in order to further understand IDO enzyme activity.
Therefore, from the IDO assay performed in the present study,
t can be concluded that untreated hMSCs do not constitutively
xpress IDO and that inﬂammatory pre-treatment is required in
rder to induce IDO secretion. It can also be proposed that the cul-
ure process, regardless of the process step utilised, may  have a
etrimental impact upon hMSC IDO expression after inﬂammatory
re-treatment, and that the automated non-centrifugation process
tep may  have a slightly greater detrimental impact upon IDO activ-
ty compared to the manual centrifugation process step.
Given the correlation between IDO production and hMSC
mmunosuppressive potential [44], any effect of the culture process
pon hMSC IDO expression may  signiﬁcantly impact their clinical
fﬁcacy, which would represent a major drawback for the manu-
acture of hMSC-based therapies. The IDO activity observed in all
nﬂammatory pre-treated hMSC conditioned medium samples was
ufﬁcient to be of clinical relevance, with Tattevin et al. [46] pre-
iously reporting that a kynurenine concentration of ≤20 M was
orrelated with an increased anti-inﬂammatory response in sepsis
atients. Therefore, as the results of the present study indicate that
ach of the inﬂammatory pre-treated hMSC conditioned medium
amples exhibited a kynurenine concentration of >20 M,  it is clear
hat each of the inﬂammatory pre-treated hMSC populations pro-
uced a clinically relevant immunosuppressive effect.
In addition to the inconsistency of the IDO assay, it must also
e recognised that the innate variability between hMSC popula-
ions may  have been likely to inﬂuence the results of this assay. For
xample, variability between donors, including age and gender, has
een found to signiﬁcantly inﬂuence hMSC gene expression and
mmune-suppressive function [47,48]. It has also been observed
hat the expansion of hMSCs in monolayer culture can lead to
lterations in gene expression, therefore creating differences in
ene expression proﬁles between populations [49,50]. Therefore,
he heterogeneous nature of these cells may  have contributed to
he non-signiﬁcant variability in IDO activity, between hMSCs cul-
ured utilising each of the alternative process steps, observed in the
resent study.ntrifugation and non-centrifugation hMSC conditioned medium samples after no
cate and the assay was  repeated. Standard deviations are plotted as error bars and
3.8.2. PGE-2 Quantiﬁcation
The PGE-2 mediated immunosuppression of hMSCs was  ﬁrst
observed in a mouse sepsis model in which bone marrow derived
stromal cells were administered [51]. It has since been deter-
mined that pro-inﬂammatory mediators activate sensors on the
MSC  membrane causing upregulation of the expression of COX2,
and other arachidonic acid pathway components, by the MSCs,
which in turn increases their PGE-2 secretion [19]. This PGE-2 neg-
ative feedback loop, for which intimate association or cell–cell
contact may  be required, stimulates the transition of resident
macrophages from their classical pro-inﬂammatory phenotype
towards an anti-inﬂammatory phenotype, in which the cells secrete
anti-inﬂammatory mediators such as IL-10 and IL-1 receptor ago-
nist [19]. PGE-2 has also been found to suppress dendritic cell
maturation, T-lymphocyte activation, T-lymphocyte proliferation,
and T-lymphocyte cytokine secretion [52,53]. Additionally, block-
ing the synthesis or activity of PGE-2, using either indomethacin
or PGE-2 blocking antibody, has also been found to prevent the
immunosuppressive effects of MSCs and allow lymphocyte prolif-
eration to be restored [54,55].
The concentration at which PGE-2 is secreted by hMSCs may
be critical in the magnitude of immunosuppressive response.
Solchaga and Zale [55] discovered that PGE-2 accurately corre-
lated with the immunosuppressive capacity of hMSCs, and thus
that increased PGE-2 expression resulted in a greater immunosup-
pressive effect. Therefore, any differences in the concentration of
PGE-2 secreted by baseline, centrifugation, or non-centrifugation
hMSCs in response to pro-inﬂammatory cytokines in the present
study may  be signiﬁcant and may  represent a substantial change in
the immunosuppressive function of these cells.
In previous experiments, Najar et al. [53] reported that, hMSCs
derived from bone marrow, Wharton’s jelly, and adipose tissue
constitutively produced PGE-2. The results of the present study
(Fig. 12) suggest that although baseline hMSCs may constitutively
secrete PGE-2, the concentration at which the PGE-2 was  produced
was very low in comparison to inﬂammatory pre-treated cells. The
data also indicates that the constitutive expression of PGE-2 in
untreated cells may  decrease with culture over two  passages, using
either manual or automated process steps over two passages, as
the concentration of PGE-2 in the conditioned medium of untreated
centrifugation (p = 0.625) and non-centrifugation (p = 0.643) hMSCs
may  have been lower than in that of the untreated baseline hMSCs,
although this was not a signiﬁcant trend.
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iig. 12. The average concentration of prostaglandin E2 (PGE-2) in baseline, centrif
NT)  or inﬂammatory pre-treatment (IN-PT). Samples were measured in triplicate,
ntreated samples (p = 0.05), and # denotes signiﬁcance over pre-treated samples (
Previous studies have identiﬁed that the stimulation of hMSCs
ith certain factors increases their PGE-2 secretion, for example,
he pro-inﬂammatory cytokine TNF- has been found to be cor-
elated with a signiﬁcant increase in the expression of PGE-2 by
MSCs [55]. In the present study, the results of the PGE-2 ELISA
llustrate that each of the pre-treated hMSC samples exhibited a
igniﬁcantly increased concentration of PGE-2 compared to the
ntreated hMSC samples, demonstrating that, similarly to IDO, an
nﬂammatory microenvironment is required to stimulate signif-
cant PGE-2 expression. The increased secretion of PGE-2 by all
re-treated hMSC groups therefore indicates that, regardless of the
ell culture process steps utilised, all of the cells demonstrated an
mmunosuppressive response to an inﬂammatory microenviron-
ent. Previous experiments have reported a similar magnitude of
GE-2 secretion in mice and human MSCs after alternative pre-
reatment and co-culture [56,57].
Furthermore, it is apparent that the inﬂammatory pre-
reatment of the non-centrifugation hMSCs induced a signiﬁcantly
reater secretion of the immunomodulatory factor PGE-2 com-
ared to that of baseline (p = 0.00) and centrifugation (p = 0.00)
MSCs. Also, no signiﬁcant difference between the PGE-2 expres-
ion of pre-treated baseline and centrifugation hMSCs was
bserved (p = 0.885). These ﬁndings contradict the non-signiﬁcant
rends observed in the IDO assay, and suggest that the culture
f hMSCs over two passages, utilising either centrifugation or
on-centrifugation process steps, had no effect upon the PGE-
 secretion, and therefore the immunosuppressive potential, of
MSCs. This data may  also indicate that the utilisation of an auto-
ated process step may  promote an increased production of PGE-2
ompared to baseline or centrifugation hMSCs.
Therefore, it can be concluded that pre-treatment with pro-
nﬂammatory cytokines was required to induce signiﬁcant PGE-2
ecretion in all hMSC groups, although culture over two  pas-
ages may  decrease constitutive PGE-2 expression. It was also
bserved that, contrary to the non-signiﬁcant trends observed in
he IDO assay, culture over two passages using either the manual
r the automated culture process steps did not decrease the hMSC
mmunosuppressive response to pro-inﬂammatory cytokines, and
hat the utilisation of the non-centrifugation process steps may
n fact increase the secretion of PGE-2 in response to an inﬂam-
atory microenvironment. It could be hypothesised that this
ncreased PGE-2 concentration in the conditioned medium of pre-n and non-centrifugation hMSC conditioned medium samples after no treatment
e averages with their standard deviations are plotted. * Denotes signiﬁcance over
5).
treated non-centrifugation hMSCs was due to an increase in the
immunosuppressive capacity of these cells, or perhaps due to a
more pro-inﬂammatory environment in the culture when utilising
the non-centrifugation process steps, resulting in a greater anti-
inﬂammatory response. However, further investigation would be
required to investigate the effects of the non-centrifugation pro-
cess steps upon the PGE-2 secretion of inﬂammatory pre-treated
hMSCs. It must also be acknowledged that, as with the IDO assay,
the heterogeneity of hMSCs may  have inﬂuenced the results of this
PGE-2 ELISA.
3.8.3. VEGF quantiﬁcation
It has previously been demonstrated, both in vitro and in vivo,
that hMSCs have the capacity to stimulate new blood vessel forma-
tion, and it has therefore become widely recognised that these cells
have a pro-angiogenic function [58,59,4,17,60]. As discussed previ-
ously, vascular endothelial growth factor (VEGF) has been strongly
linked to the angiogenic potential of hMSCs [61–64]. Additionally,
it has been proposed that this growth factor plays a critical role in
hMSC pro-angiogenic function [21–26].
A signiﬁcant body of research regarding the preconditioning of
hMSCs in low oxygen concentrations has identiﬁed that, although
hMSCs constitutively express VEGF in normal oxygen concentra-
tions, exposing these cells to a low partial pressure of oxygen, or
hypoxia, stimulates the increased expression of VEGF [20–25,65].
Therefore, it has been concluded that by pre-treating hMSCs in
hypoxic conditions the expression of VEGF by these cells will be
increased, which will in turn improve their pro-angiogenic func-
tion. A number of investigators have demonstrated the increased
angiogenic potential of hypoxia preconditioned hMSCs and have
found that these pre-treated cells increase endothelial cell growth
in vitro [21,24] and improve perfusion in rodent hind limb
ischaemia models [21,22].
The results of the VEGF ELISA performed in the present study
concur with the literature and demonstrated that all untreated
hMSC populations constitutively expressed VEGF. However, it was
also observed that both untreated centrifugation (p = 0.06) and
non-centrifugation (p = 0.00) hMSCs secreted signiﬁcantly lower
concentrations of VEGF compared to untreated baseline hMSCs.
This may  suggest that, regardless of the process step utilised, the
culture of these cells over two passages decreased their VEGF
expression under normoxic conditions (20% O2). However, it has
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cig. 13. The average concentration of vascular endothelial growth factor (VEGF) in b
o  treatment (NT) or hypoxic pre-treatment (HY-PT). The samples were measured in
ver  all samples (p = 0.05), and # denotes signiﬁcance over pre-treated samples (p =
reviously been demonstrated that both rat and human MSCs
aintain, or even increase, their VEGF secretion over multiple pas-
ages [26,66]. Additionally, this same pattern was not observed
hen the hMSCs were cultured under hypoxic conditions.
Fig. 13 also illustrates that hypoxic pre-conditioning, at 1%
2, did not signiﬁcantly increase hMSC VEGF production. No sig-
iﬁcant difference in VEGF concentration of hMSC conditioned
edium samples was observed between untreated centrifugation
nd untreated non-centrifugation hMSCs compared to all hypoxia
re-treated hMSCs. Furthermore, it is apparent that untreated base-
ine hMSCs secreted signiﬁcantly greater concentrations of VEGF
ompared to untreated centrifugation (p = 0.06), untreated non-
entrifugation (p = 0.02), hypoxia pre-treated baseline (p = 0.00),
ypoxia pre-treated centrifugation (p = 0.039), and hypoxia pre-
reated non-centrifugation (p = 0.00) hMSCs. Although substantial
vidence supporting increased VEGF expression by hypoxic pre-
onditioned hMSCs exists, a failure to demonstrate this pattern has
een previously reported in which hMSCs were cultured at 1% O2
s a monolayer [67].
Additionally, these results illustrate that hypoxia pre-treated
entrifugation hMSCs may  have produced a greater angiogenic
esponse to hypoxic preconditioning compared to hypoxia pre-
reated baseline (p = 0.09) and non-centrifugation hMSCs (p = 0.05)
y secreting a greater concentrations of VEGF into the culture
edium. From this ﬁnding, it could be proposed that the man-
al centrifugation process step has the capacity to increase the
xpression of VEGF by hMSCs. However, although hypoxic pre-
onditioning may  facilitate this increase cooperatively with the
entrifugation process, as this ﬁnding was not observed in the
ntreated centrifugation hMSC samples, this hypothesis cannot be
upported and therefore further investigation is required.
As discussed previously, with regards the results of the IDO assay
nd PGE-2 ELISA in the present study, it must be acknowledged
hat, despite the observation of differences in VEGF expression
etween hMSCs cultured using each of the process steps, the
eterogeneous nature of hMSC populations may  signiﬁcantly inﬂu-
nce these results. Variability in hMSC characteristics can often be
bserved due to donor variability or inconsistency in the manufac-
uring process [68], leading to heterogeneity between populations.. Conclusions
From the present study, it can be concluded that no signiﬁ-
ant difference in hMSC morphology, surface marker expression,e, centrifugation and non-centrifugation hMSC conditioned medium samples after
cate, and the averages and standard deviations were plotted. * Denotes signiﬁcance
.
STR proﬁle, viable cell yield, and viability was observed between
hMSCs cultured using either the manual centrifugation step or
the automated non-centrifugation process step, in which resid-
ual dissociation agent is carried over. Surface marker proﬁle was
concordant for the majority of hMSC markers between ﬂow cytom-
etry analyses performed at two  independent laboratories; however,
differences in culture and analysis methods between laboratories
may  have contributed to the variability observed in two of the
surface markers. Additionally, all hMSC samples responded to pro-
inﬂammatory pre-treatment (TNF-  & IFN-) by expressing PGE-2
and IDO, although none of the hMSC samples signiﬁcantly upreg-
ulated VEGF expression in response to hypoxic pre-treatment (1%
O2). Although differences in PGE-2, VEGF and IDO expression, in
response to hypoxic and pro-inﬂammatory pre-treatment, were
observed between hMSCs cultured utilising manual and automated
process steps, the innate heterogeneity of hMSCs may contribute to
these ﬁndings. Finally, the results of the present study also suggest
that the utilisation of the automated non-centrifugation process
step may  result in greater variability in viable hMSC yield.
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